MarketPulse

Phase 2 clinical trial

17 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biomea Fusion to Present Icovamenib Diabetes Data at ADA Conference

Biomea Fusion selected for three late-breaking poster presentations on icovamenib at ADA 86th Scientific Sessions in June 2026, showcasing Phase 2 trial results.
BMEAPhase 2 clinical trialType 1 diabetes
BenzingaBenzinga··Prnewswire

Anixa Biosciences Secures Mexican Patent for Breast Cancer Vaccine Through 2040

Anixa Biosciences secures Mexican patent for breast cancer vaccine extending protection through 2040, supporting Phase 2 trial advancement.
ANIXPhase 2 clinical trialintellectual property
GlobeNewswire Inc.GlobeNewswire Inc.··Allarity Therapeutics

Allarity Therapeutics Secures Patent Allowance for Stenoparib Companion Diagnostic

Allarity Therapeutics received USPTO notice of allowance for stenoparib DRP® companion diagnostic patent, providing exclusivity through 2039.
ALLRPhase 2 clinical trialstenoparib
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kyowa Kirin, Kura Oncology Launch Japanese Phase 2 Trial for FDA-Approved Ziftomenib

Kyowa Kirin and Kura Oncology begin Japanese Phase 2 registrational trial for ziftomenib in relapsed/refractory NPM1-mutated AML, following FDA approval.
KURAPhase 2 clinical trialhematologic malignancies
GlobeNewswire Inc.GlobeNewswire Inc.··Na

AIM ImmunoTech Flags Going Concern Despite Clinical Trial Progress

AIM ImmunoTech disclosed going concern warnings in 2025 audited statements but expressed confidence in fundraising backed by promising Ampligen-Imfinzi trial results.
AZNAIMPhase 2 clinical trialfundraising
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Neurocrine Advances Nxera's Schizophrenia Drug into Phase 2 with First Patient Dosed

Neurocrine Biosciences doses first patient in Phase 2 trial of NBI-1117570 for schizophrenia, triggering $22.5M milestone payment to partner Nxera Pharma.
NBIXPhase 2 clinical trialdrug discovery
GlobeNewswire Inc.GlobeNewswire Inc.··Okyo Pharma Limited

OKYO Pharma to Showcase Urcosimod Data at ASCRS Meeting Ahead of Late-Stage Trial

OKYO Pharma presents Phase 2 urcosimod data at ASCRS conference; plans Phase 2b/3 trial launch in H1 2026 for neuropathic corneal pain.
OKYOPhase 2 clinical trialbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nasus Pharma Advances NS002 to Pivotal Stage on Positive Phase 2 Data

Nasus Pharma reports positive Phase 2 data for NS002 intranasal epinephrine, planning pivotal study Q4 2026 with strong cash position through Q2 2027.
NSRXPhase 2 clinical trialPivotal Study
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Gain Therapeutics to Showcase Parkinson's Drug Progress at Major Medical Conferences

Gain Therapeutics will present Phase 1b data for Parkinson's treatment GT-02287 at major conferences, with CEO appearing at ROTH Conference on March 23, 2026.
GANXPhase 2 clinical trialParkinson's disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Acumen Pharma to Unveil 2025 Results as Alzheimer's Drug Advances

Acumen Pharmaceuticals will report full-year 2025 financial results on March 26, 2026, as its lead Alzheimer's candidate progresses through Phase 2 trials.
HALOABOSPhase 2 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Structure Therapeutics Inc.

Structure Therapeutics' Aleniglipron Posts Blockbuster Phase 2 Data, Rivaling Injectable GLP-1s

Structure Therapeutics reports Phase 2 data for oral GLP-1 agonist aleniglipron showing 16.3% weight loss, matching injectable competitors with better tolerability.
GPCRPhase 2 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Incannex Healthcare Inc.

Incannex Accelerates Sleep Apnea Drug After FDA Fast Track Win, Phase 2 Success

Incannex Healthcare receives FDA Fast Track Designation for IHL-42X sleep apnea treatment following positive Phase 2 results, plans optimized Phase 3 pathway.
IXHLPhase 2 clinical trialdrug development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Acumen Pharma to Present Alzheimer's Drug Data at Stifel CNS Forum

Acumen Pharmaceuticals to present Alzheimer's drug candidate sabirnetug at Stifel CNS Forum on March 18, 2026, as Phase 2 trials advance.
HALOABOSPhase 2 clinical trialmonoclonal antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Aligos Therapeutics, Inc.

Aligos Therapeutics Cuts Losses 82% While Advancing Hepatitis B Pipeline

Aligos reports $24.2M net loss in 2025, down 82% YoY. Key hepatitis B study enrollment complete; cash runway extends to Q3 2026.
ALGSPhase 2 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Upstream Bio, Inc.

Upstream Bio's Verekitug Shows Strong Phase 2 Results in Nasal Polyp Treatment

Upstream Bio presented additional Phase 2 data for verekitug in chronic rhinosinusitis with nasal polyps, meeting primary endpoints with significant surgical intervention reduction.
UPBPhase 2 clinical trialmonoclonal antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Celldex Touts Sustained Efficacy Data for Mast Cell Antibody Barzolvolimab

Celldex's mast cell antibody barzolvolimab showed strong Phase 2 efficacy for urticaria, with 71% of patients achieving complete response. Phase 3 data expected Q4 2026.
CLDXbarzolvolimabchronic spontaneous urticaria
GlobeNewswire Inc.GlobeNewswire Inc.··Upstream Bio, Inc.

Upstream Bio to Unveil Extended VIBRANT Trial Data on Verekitug at AAAAI 2026

Upstream Bio will present expanded VIBRANT trial data on verekitug for chronic rhinosinusitis with nasal polyps at AAAAI 2026, including new efficacy analyses accounting for rescue therapy use.
UPBPhase 2 clinical trialmonoclonal antibody